Positive Preclinical Data with Transition Therapeutics Alzheimer's Disease Drug Candidate AZD-103
Transition Therapeutics Inc. announced that Nature medicine has published an online version of a publication of preclinical studies with Transition's lead Alzheimer's disease drug candidate, AZD-103. The AZD-103 compound is a possible disease-modifying therapeutic drug candidate for the treatment of Alzheimer's disease. This unique class of drug candidates may provide significant advantages over the current therapies on the market. The findings in the Nature Medicine publication show that oral treatment of AZD-103 (scyllo-cyclohexanehexol) reduces accumulation of amyloid beta and amyloid beta plaques in the brain, as well as reduces or eliminates learning deficits in a transgenic mouse model of Alzheimer's disease. Transition is pursuing the clinical drug development of AZD-103 in an expedited manner.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.